Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

CRPS-Hand: Contrast + Compression vs Whirlpool

1 août 2026 mis à jour par: Gizem Suna Tuncer, Ankara Etlik City Hospital

Combined Contrast Therapy and Intermittent Compression vs Whirlpool Therapy in Post-Traumatic Hand and Wrist CRPS: A Randomized Controlled Trial

This randomized controlled trial aims to evaluate and compare the effectiveness of combined contrast therapy with intermittent compression and whirlpool therapy in patients with post-traumatic CRPS-I of the hand and wrist, using objective outcome measures of pain, edema, and functional status.

Aperçu de l'étude

Description détaillée

Complex Regional Pain Syndrome Type 1 (CRPS-I) is a condition that may develop after upper extremity trauma, surgical interventions, or central nervous system disorders, leading to chronic pain and functional impairment. Hydrotherapy modalities such as whirlpool and contrast bath therapy are commonly used; however, comparative evidence with combined thermal and compression-based systems remains limited.

Combined contrast therapy with intermittent compression is a non-invasive intervention delivered using the Game Ready MED4 Elite device, which integrates thermal therapy (cold-warm) with intermittent pneumatic compression (IPC). Evidence, particularly from postoperative orthopedic settings, suggests that this approach may reduce pain and edema and promote functional recovery. Cryotherapy reduces inflammation and vascular permeability, thermotherapy promotes vasodilation and tissue relaxation, and intermittent pneumatic compression (IPC) enhances venous and lymphatic return, supporting regional circulation.

The whirlpool method is a commonly used adjunctive physical therapy modality in CRPS-I treatment, involving immersion of the affected extremity in circulating water at 38-40°C. This technique provides both thermal and mechanical stimulation, promoting regional circulation, reducing muscle spasm, and facilitating edema drainage. Additionally, the gentle massaging effect of water turbulence may contribute to pain modulation and tissue relaxation.

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Gizem Suna Tuncer, MD, Specialist Physician
  • Numéro de téléphone: +905347953185
  • E-mail: sunagizem05@gmail.com

Lieux d'étude

    • Yenimahalle
      • Ankara, Yenimahalle, Turquie (Türkiye), 06370
        • Recrutement
        • Etlik City Hospital, Department of Physical Medicine and Rehabilitation
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Patients diagnosed with Complex Regional Pain Syndrome Type 1 (CRPS-I) according to the Budapest Criteria
  • Age between 18 and 80 years
  • CRPS developed following upper extremity trauma (e.g., hand or wrist fracture, soft tissue injury)
  • Symptom duration less than 3 months (subacute stage)
  • Ability and willingness to provide written informed consent and voluntarily participate in the study

Exclusion Criteria:

  • Patients diagnosed with Complex Regional Pain Syndrome Type 2 (CRPS-II) or with evidence of peripheral nerve injury
  • History of peripheral neuropathy, Raynaud's phenomenon, or vascular circulation disorders
  • Presence of impaired skin integrity, open wounds, infection, or dermatological disease in the affected area
  • History of cold or heat intolerance, cold urticaria, or hypersensitivity to thermal modalities
  • Active infection or severe edema in the affected extremity
  • Presence of serious systemic diseases (cardiovascular, pulmonary, renal, or neurological)
  • Receipt of similar physical therapy or modality-based treatment within the past 3 months

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Combined Contrast Therapy with Intermittent Compression
Participants in this group will receive combined contrast therapy with intermittent pneumatic compression in addition to a standardized exercise program. The intervention will be delivered over a 3-week period (5 sessions/week, 15 sessions in total). Combined contrast therapy will integrate alternating hot and cold thermal therapy with intermittent pneumatic compression. The standardized exercise program will include supervised range-of-motion, stretching, and upper extremity mobility exercises targeting the wrist and hand.

This non-invasive intervention will be delivered using the Game Ready MED4 Elite device, which integrates thermal therapy (hot-cold) with intermittent pneumatic compression (IPC). The device is capable of simultaneously providing contrast therapy and intermittent pneumatic compression and is widely used in upper and lower extremity rehabilitation.

Rapid Contrast Therapy Protocol:

Heat application: Applied at 39 °C for 3 minutes Cold application: Applied at 15 °C for 1 minute, with mild compression during the cold phase Cycle duration: The heat-cold cycle will be repeated continuously for a total of 15 minutes

Autres noms:
  • Game Ready System
  • Cold and Compression Therapy
Comparateur actif: Whirlpool Therapy

Participants in this group will receive whirlpool therapy along with a standardized exercise program. The intervention will be administered over a 3-week period, 5 sessions per week, for a total of 15 sessions.

Whirlpool therapy will be applied by immersing the affected hand and wrist in circulating water maintained at 40 °C, providing both thermal and mechanical stimulation.

The standardized exercise program will include supervised range-of-motion, stretching, and upper extremity mobility exercises targeting the wrist and hand.

Whirlpool therapy is a hydrotherapy modality used to enhance circulation in the upper extremity, reduce muscle spasm, alleviate pain, and facilitate edema resolution. In this study, a Technomex® whirlpool device will be used for hydrotherapy applications. The water temperature will be set at 40 °C and continuously monitored with a thermometer.

The device motor will generate a circular turbulent water flow. The patient's hand and wrist will be positioned comfortably in the tank without compromising circulation.

The duration of each session will be 15 minutes.

Autres noms:
  • Hydrothérapie
  • Technomex Whirlpool Device

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Visual Analog Scale (VAS)
Délai: At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up).
Patients rate their pain on a 0-10 scale. A lower score indicates reduced pain.
At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Hand Function (QuickDASH)
Délai: At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up).
The Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire is a brief and practical tool used to assess upper extremity functional status and its impact on daily activities. It is the short form of the original DASH questionnaire and consists of 11 items. Participants rate their difficulty in performing daily activities involving the arm, shoulder, and hand using a 5-point Likert scale. Scores are standardized on a 0-100 scale, where 0 indicates no disability and 100 indicates the highest level of disability.
At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up).
Neuropathic Pain Assessment (LANSS)
Délai: at baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Neuropathic pain will be evaluated using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale. This tool assesses pain characteristics and sensory dysfunction through a combination of patient-reported symptoms and clinical examination findings. The total score ranges from 0 to 24, with scores ≥12 suggesting the presence of neuropathic pain.
at baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Edema Measurement (Circumferential Measurement)
Délai: at baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Edema will be assessed using circumferential measurements with a measuring tape at the wrist and palm. Wrist circumference will be measured just proximal to the distal radioulnar joint, and palm circumference will be measured at the widest level across the metacarpal heads. Measurements will be performed with the patient in a relaxed sitting or standing position, with the hand and wrist in a neutral position and the limb supported to avoid muscle contraction. The tape will be applied gently without compression. Two to three measurements will be taken at each site, and the average value will be recorded.
at baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Range of Motion (ROM) and Finger-to-Palm Crease Distance (FT-PCD)
Délai: At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Wrist range of motion will be assessed by measuring wrist flexion and extension using a standard hand goniometer. The patient will be positioned in sitting with the shoulder in neutral position, the elbow at 90° flexion, the forearm in neutral rotation, and the wrist in a neutral position. Each movement will be measured 2-3 times, and the average value will be recorded.
At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Hand Grip Strength (HGS)
Délai: at baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Hand grip strength will be measured using a Jamar hand dynamometer (Jamar, USA) in accordance with the standardized position recommended by the American Society of Hand Therapists. Participants will be seated with the shoulder in adduction and neutral rotation, the elbow at 90° flexion, the forearm in neutral position, and the wrist in a neutral position. Three measurements will be performed for each participant with a 1-minute rest interval between trials, and the average value will be recorded. Grip strength will be expressed in kilograms-force (kgf).
at baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Finger-to-Palm Crease Distance (FT-PCD)
Délai: At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)
Finger-to-palm crease distance (FT-PCD) will be measured in centimeters as the distance between the tip of the third finger and the distal palmar crease. This measurement will be used to quantitatively assess limitations in finger flexion associated with edema and joint stiffness.
At baseline, at 3 weeks (end of treatment), and at 7 weeks (follow-up)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Gizem Suna Tuncer, MD, Specialist Physician, Ankara Etlik City Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 mai 2026

Achèvement primaire (Estimé)

30 avril 2027

Achèvement de l'étude (Estimé)

30 juillet 2027

Dates d'inscription aux études

Première soumission

19 juillet 2026

Première soumission répondant aux critères de contrôle qualité

1 août 2026

Première publication (Réel)

4 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

1 août 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner